title: Molecular imaging of hypoxia in non-small-cell lung cancer.
abstract: Non-small-cell lung cancer (NSCLC) is the commonest cancer worldwide but survival remains poor with a high risk of relapse, particularly after nonsurgical treatment. Hypoxia is present in a variety of solid tumours, including NSCLC. It is associated with treatment resistance and a poor prognosis, although when recognised may be amenable to different treatment strategies. Thus, noninvasive assessment of intratumoral hypoxia could be used to stratify patients for modification of subsequent treatment to improve tumour control. Molecular imaging approaches targeting hypoxic cells have shown some early success in the clinical setting. This review evaluates the evidence for hypoxia imaging using PET in NSCLC and explores its potential clinical utility.
authors.affiliation: Department of Cancer Imaging, Division of Imaging Sciences & Biomedical Engineering, King's College London, St Thomas' Hospital, London, UK, connie.yip@kcl.ac.uk.
authors.forename: Connie
authors.initials: C
authors.lastname: Yip
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Blower
authors.forename: Vicky
authors.initials: V
authors.lastname: Goh
authors.forename: David B
authors.initials: DB
authors.lastname: Landau
authors.forename: Gary J R
authors.initials: GJ
authors.lastname: Cook
mesh_terms: D000818:Animals; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging* / Q000378:metabolism; D015687:Cell Hypoxia; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism; D010100:Oxygen / Q000378:metabolism*; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology
chemical_list: D019275:Radiopharmaceuticals; D010100:Oxygen